A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12).
Dong Ki LeeSook Ryun ParkYeul Hong KimYun-Gyoo LeeSu-Jin ShinBeung-Chul AhnSung Sook LeeSun Min LimHye Ryun KimByoung Chul ChoMin Hee HongPublished in: Oncoimmunology (2024)
The trial was registered at ClinicalTrials.gov under the identifier NCT03785496.